Biolase Inc

Find Ratings Reports
BIOL : NASDAQ : Health Care
$1.11 | %
Today's Range: 0.00 - 0.00
Avg. Daily Volume: 45,100
07/26/16 - 3:59 PM ET

Financial Analysis


BIOLASE INC's gross profit margin for the first quarter of its fiscal year 2016 has increased when compared to the same period a year ago. The company has grown sales and net income during the past quarter when compared with the same quarter a year ago, however, it was unable to keep up with the growth of the average competitor within its industry. BIOLASE INC has average liquidity. Currently, the Quick Ratio is 1.16 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 41.84% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)11.0110.86
EBITDA ($mil)-4.1-5.83
EBIT ($mil)-4.31-5.99
Net Income ($mil)-4.27-5.44


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)6.8323.94
Total Assets ($mil)38.4254.69
Total Debt ($mil)0.160.49
Equity ($mil)21.5937.13


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin35.0230.51
EBITDA Margin-37.24-53.72
Operating Margin-39.17-55.18
Sales Turnover1.270.86
Return on Assets-49.73-35.6
Return on Equity-88.48-52.45
Debt Q1 FY16 Q1 FY15
Current Ratio2.143.11
Debt/Capital0.010.01
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)58.2658.15
Div / share0.00.0
EPS-0.07-0.09
Book value / share0.370.64
Institutional Own % n/a n/a
Avg Daily Volume44198.084879.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 2.70 indicates valuation on par with the S&P 500 average of 2.81 and a significant discount versus the industry average of 4.84. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. After reviewing these and other key valuation criteria, BIOLASE INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
BIOL NM Peers 62.82   BIOL NM Peers 33.31

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

BIOL's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

BIOL's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
BIOL NM Peers 29.14   BIOL NA Peers 1.03

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

BIOL's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
BIOL 2.70 Peers 4.84   BIOL 23.81 Peers 159.18

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

BIOL is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, BIOL is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
BIOL 1.20 Peers 4.71   BIOL 3.48 Peers 20.16

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

BIOL is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

BIOL significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades